News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2020 Just One-Third of European Patients Get to LDL Cholesterol Goals Michael O'Riordan October 13, 2020
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2017 Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage Yael L. Maxwell April 27, 2017